Buscar

22/09/2022 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Dohner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Rollig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Lowenberg, B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. BLOOD. 2022; 140(12)DOI:10.1182/blood.2022016867. PMID:35797463. IF:20.300(Q1/1D).
15/09/2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, Wang, SA, Bagg, A, Barbui, T, Branford, S, Bueso-Ramos, CE, Cortes, JE, Dal Cin, P, DiNardo, CD, Dombret, H, Duncavage, EJ, Ebert, BL, Estey, EH, Facchetti, F, Foucar, K, Gangat, N, Gianelli, U, Godley, LA, Gokbuget, N, Gotlib, J, Hellstrom-Lindberg, E, Hobbs, GS, Hoffman, R, Jabbour, EJ, Kiladjian, JJ, Larson, RA, Le Beau, MM, Loh, MLC, Lowenberg, B, Macintyre, E, Malcovati, L, Mullighan, CG, Niemeyer, C, Odenike, OM, Ogawa, S, Orfao, A, Papaemmanuil, E, Passamonti, F, Porkka, K, Pui, CH, Radich, JP, Reiter, A, Rozman, M, Rudelius, M, Savona, MR, Schiffer, CA, Schmitt-Graeff, A, Shimamura, A, Sierra, J, Stock, WA, Stone, RM, Tallman, MS, Thiele, J, Tien, HF, Tzankov, A, Vannucchi, AM, Vyas, P, Wei, AH, Weinberg, OK, Wierzbowska, A, Cazzola, M, Dohner, H, Tefferi, A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. BLOOD. 2022; 140(11)DOI:10.1182/blood.2022015850. PMID:35767897. IF:20.300(Q1/1D).
01/05/2022 An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022)
Jimenez, AJM, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022). BONE MARROW TRANSPLANTATION. 2022; 57(5)DOI:10.1038/s41409-022-01625-6. PMID:35297406. IF:4.800(Q1/2D).
01/01/2022 CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center
Arguello-Tomas M., Albiol N., Jara P., Sierra J., Mora A., Moreno C.. CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01349-0. PMID:36163896. IF:(Q/D).
01/01/2022 CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Santos M.F., Almorox R.B., Solan L., Lopez O., Gallardo A., Garcia-Avila S., Esquirol A., Ferra C., Martin A., Garcia A., Perez E., Colorado M., Cortes M., Cabrero M., Gayoso J., Yañez L., Pascual M.J., Heras I.D.L., Diez J.L., Caballero M.D., Kwon M., Corral L.L.. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:(Q/D).
01/01/2022 CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).